Appoints Mark R. Bamforth as CEO to Drive Growth at Kincell Bio
Appoints Mark R. Bamforth as CEO to Drive Growth at Kincell Bio Kincell Bio, a leader in the cell therapy development and manufacturing sector, appoints Mark R. Bamforth as Chief…
Category Press Releases
Read MoreAppoints Mark R. Bamforth as CEO to Drive Growth at Kincell Bio
Announces Milestone KarXT NDA Acceptance for Schizophrenia, Zai Lab
Announces Milestone KarXT NDA Acceptance for Schizophrenia, Zai Lab Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announces that China’s National Medical Products Administration (NMPA) has accepted the New Drug…
FDA Approves FoundationOne®CDx for OJEMDA™ in Pediatric Brain Tumor
FDA Approves FoundationOne®CDx for OJEMDA™ in Pediatric Brain Tumor Foundation Medicine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved FoundationOne®CDx as a companion diagnostic for…
Agreement Between Neuraly and Enigma Biomedical USA on PET Imaging Biomarker PMI04
Agreement Between Neuraly and Enigma Biomedical USA on PET Imaging Biomarker PMI04 On January 16, 2025, Neuraly Inc., a wholly owned subsidiary of D&D Pharmatech Inc., and Enigma Biomedical USA,…
Healthcare Empowered: Vim Launches Care Insights for Smarter, Data-Driven Decisions
Healthcare Empowered: Vim Launches Care Insights for Smarter, Data-Driven Decisions Vim, a leader in connected healthcare technology and clinical workflow integration, has announced the launch of Care Insights, a revolutionary…
Massive Bio Recognized by White House Cancer Moonshot, Launches $15M Initiative at JPM 2025
Massive Bio Recognized by White House Cancer Moonshot, Launches $15M Initiative at JPM 2025 Massive Bio is proud to announce its inclusion in the White House Office of Science &…
Reports Positive Results from RESTORE Trial of ReActiv8® by Mainstay Medical
Reports Positive Results from RESTORE Trial of ReActiv8® by Mainstay Medical Mainstay Medical Holdings plc reports today the publication of positive one-year results from the RESTORE randomized clinical trial of…
GenSight Biologics Announces Groundbreaking 5-Year Outcomes for Unilateral LUMEVOQ® Gene Therapy
GenSight Biologics Announces Groundbreaking 5-Year Outcomes for Unilateral LUMEVOQ® Gene Therapy GenSight Biologics (Euronext: SIGHT) has announced the publication of five-year follow-up data for patients treated with its investigational gene…
Results: Castle Biosciences Reports Preliminary Q4 and 2024 Performance
Results: Castle Biosciences Reports Preliminary Q4 and 2024 Performance Castle Biosciences, Inc. (Nasdaq: CSTL), a company dedicated to improving patient care through innovative tests, today announced preliminary unaudited performance results…
Cigna Foundation Grants Support Veterans’ Mental Health and Housing
Cigna Foundation Grants Support Veterans’ Mental Health and Housing The Cigna Group Foundation recently announced the 22 recipients for its inaugural year of a new grant program designed to support…
City Therapeutics Teams Up with Bausch + Lomb on RNAi Treatment for Geographic Atrophy
City Therapeutics Teams Up with Bausch + Lomb on RNAi Treatment for Geographic Atrophy City Therapeutics, Inc., a biopharmaceutical leader in RNA interference (RNAi)-based medicine, has announced a strategic collaboration…
Free Testosterone Test: Revvity Receives FDA Clearance for First Automated Assay
Free Testosterone Test: Revvity Receives FDA Clearance for First Automated Assay Revvity, Inc. (NYSE: RVTY), a global leader in health science solutions, has announced that it has received 510(k) clearance…